Disease-free survival following salvage cryotherapy for biopsy-proven radio-recurrent prostate cancer

European Urology

Volumn 60, Issue 3, 2011, Pages 405-410

  Williams, Andrew K ^a   Martínez, Carlos H ^a   Lu, Chen ^a   Ng, Chee Kwan ^b   Pautler, Stephen E ^a   Chin, Joseph L ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

Cryotherapy; Prostate cancer; Radiation; Recurrence

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CRYOTHERAPY; DISEASE FREE SURVIVAL; FOLLOW UP; FREEZE THAWING; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; RETROSPECTIVE STUDY; SALVAGE THERAPY; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT OUTCOME;

AGED; ANDROGEN ANTAGONISTS; BIOPSY; BRACHYTHERAPY; CHI-SQUARE DISTRIBUTION; CRYOTHERAPY; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; ONTARIO; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SALVAGE THERAPY; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 79960979950     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2010.12.012     Document Type: Article

References (18)

1. Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol 2010;28:1106-11.
2. Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR, Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE). Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer 2008;112:307-14.
3. Nguyen PL, D'Amico AV, Lee AK, Suh WW. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer 2007;110:1417-28. (Pubitemid 47463054)
4. Ng CK, Moussa M, Downey DB, Chin JL. Salvage cryoablation of the prostate: followup and analysis of predictive factors for outcome. J Urol 2007;178:1253-7, discussion 1257.
5. Pisters LL, Rewcastle JC, Donnelly BJ, Lugnani FM, Katz AE, Jones JS. Salvage prostate cryoablation: initial results from the cryo on-line data registry. J Urol 2008;180:559-63, discussion 563-4.
6. Blana A, Brown SC, Chaussy C, et al. High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure. BJU Int 2009;104:1058-62.
7. Pisters LL, Leibovici D, Blute M, et al. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy. J Urol 2009;182:517-27.
8. Williams A, Martinez C, Chalasani V, Lu C, Ng C, Chin J. Long-term results of salvage cryotherapy for prostate cancer. CUAJ 2010;4(Suppl):S4.
9. Izawa JI, Madsen LT, Scott SM, et al. Salvage cryotherapy for recurrent prostate cancer after radiotherapy: variables affecting patient outcome. J Clin Oncol 2002;20:2664-71. (Pubitemid 34575639)
10. Chin JL, Pautler SE, Mouraviev V, Touma N, Moore K, Downey DB. Results of salvage cryoablation of the prostate after radiation: identifying predictors of treatment failure and complications. J Urol 2001;165:1937-41, discussion 1941-2.
11. Basaria S. Prostate cancer: cardiovascular mortality and androgen deprivation. Nat Rev Urol 2009;6:252-3.
12. Efstathiou E, Logothetis CJ. Prostate cancer: thalidomide for prostate cancer: is there progress? Nat Rev Urol 2009;6:248-50.
13. Alibhai SM, Duong-Hua M, Sutradhar R, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009;27:3452-8.
14. Isbarn H, Boccon-Gibod L, Carroll PR, et al. Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol 2009;55:62-75.
15. Keating NL, O'Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010;102:39-46.
16. Amling CL, Lerner SE, Martin SK, Slezak JM, Blute ML, Zincke H. Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer. J Urol 1999;161:857-62, discussion 862-3.
17. Spiess PE, Lee AK, Leibovici D, Wang X, Do KA, Pisters LL. Presalvage prostate-specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy. Cancer 2006;107:275-80. (Pubitemid 44036556)
18. Levy DA, Pisters LL, Jones JS. Prognostic value of initial prostate-specific antigen levels after salvage cryoablation for prostate cancer. BJU Int 2010;106:986-90.